Summary of Clinical Features and Laboratory Results in Patients with Positive Intraocular

Summary of Clinical Features and Laboratory Results in Patients with Positive Intraocular

<p>Summary of Clinical features and Laboratory Results in Patients with Positive Intraocular Test (16 Toxoplasma, 6 Herpesviridae related).</p><p>Laboratory Results Case No/ age (years) Immune status Duration of symptoms Intraocular inflammation Clinical findings/site of PCR analysis Goldmann Witmer coefficient/ before intraocular AC retinal necrosis/ area of Serology: IgM Toxo if present, IgG Toxo sampling chorioretinitis Pathogen Toxoplasma gondii 1/ 35 Active C Hepatitis (IS) 4 M P Panuveitis, nasal, focal/ Toxo Pos Toxo Neg 6DP PCR VZV + VZV Pos/ coeff 2.19 IgM Toxo+</p><p>2/ 14 - 7ds P Panuveitis, , Vascularitis, Toxo Pos Toxo Neg hyalitis +, papilloedema/ HSV Pos/ coeff 3.4 ST, focal peripheral/ 4DP IgM-</p><p>3/ 72 Systemic corticotherapy 2 M P Panuveitis, hyalitis 3+, Toxo Pos Toxo Pos/ 2.9 Prednisolone 10mg/d focal, post pole / NC</p><p>4/ 68 - 21ds P Panuveitis, hyalite nil, Toxo Pos Toxo Pos/ 3.9 Vasculitis/ nasal, focal/ IgM Toxo+ 1/2 DP 5/ 24 - <7ds P Panuveitis, focal, ST/ Toxo Pos Toxo Neg NC IgM Toxo+ 6/59 - 7ds P Tyndall ½+, focal post Toxo Pos Toxo Pos/ 2.26 pole /NC IgM Toxo+</p><p>7/59 Bone marrow 3M P Tyndall+, hyalitis2+/ Toxo Pos Toxo Pos/ 4.59 transplantation, focal, nasal/ >3DP IgG 300 neutropenia (IS) 8/51 - 48h P Panuveitis granul, old sup Toxo Pos Toxo Neg ATCD 1995 lesions, hyalitis++/ 2DP IgG 44 9/37 - 21ds P Panuveitis, , hyalitis+++, Toxo Pos Toxo Pos/ 2.4 1 old scar/ sup focal, / 1 IgG 87 DP 10/35 - 1 M P Panuveitis, sup focal/ 7 Toxo Pos Toxo Pos/ 5 DP HSV Pos/ coff 2.5 11/12 - 19ds N hyalitis+, vasculitis/ ST Toxo Pos Toxo Pos/ 10.14 focal/ 3DP IgG 82.5</p><p>12/ 67 - 1 M N papillitis vasculitis, Toxo Pos Toxo Pos/ 3.27 hyalitis+++, tyndall++/ IgG 82.5 focal, scar/ 4DP 13/ 25 - 6 weeks N hyalitis++ papillitis/ Toxo Pos Toxo Pos/ 7.85 focal, post pole scar/ 3DP IgG 41.3</p><p>14/ 18 - 7 ds N Papillitis , hyalitis nil Toxo Pos Toxo Pos/ 3.08 Vasculitis, Neuroretinitis IgG 165</p><p>15/ 58 - 2 M N Tyndall 0, hyalitis 2+/ Toxo Pos Toxo Pos/ 9,7 sup, focal/ 3 DP 16/18 - 21 ds N Tyndall nil/ ST lesion, NP Toxo Pos/ 24.78 scars/ 1 DP 17/ 20 - 15 ds N vasculitis papillitis/ ST, NP Toxo Pos/ 8.45 focal, scar /2DP 18/ 59 - 6 ds N Hyalitis ½+/ multifocal NP Toxo Pos/ 11.3 focal IT, scars/ 1DP IgG 330 19/ 33 - 5 ds P Panuveitis granul, Toxo neg Toxo Pos Hyalitis 3+/ focal, IT 5.65 2DP IgG 37.5 20/ 47 - 15 ds P Panuveitis granul, Toxo Neg Toxo Pos / 2.19 Hyalitis 3+, /post pole IgG300 lesion/ 1DP 21/ 62 15 ds P Panuveitis non granul/ Toxo Neg Toxo Pos /2.45 ST, scars/ 1DP IgG 150 22/ 29 - 10 ds P Panuveitis, papillitis/ NP Toxo Pos / 12.23 focal, scars, Neuroretinitis/ 0 23/ 58 - 15 M N Scar, ERM post toxo/ 0 NP Toxo Pos / 24</p><p>24/ 30 - 7 ds N Multifocal, SN /1/6 DP Toxo Neg Toxo Pos /6</p><p>Herpes Virus 25/ 63 Breast cancer 1 M Retinitis CMV Pos CMV Pos/ 2 (chemotherapy) 26/ 37 HIV infection 24h Retinitis CMV Pos Viral neg/ IgG CMV 188</p><p>27/ 52 HIV infection 8 ds PORN Retinitis CMV Pos Viral neg 28/ 49 - 4 ds ARN HSV1 Pos Viral Neg</p><p>29/ 25 10 wks ARN HSV2 Pos HSV2 Pos 29 </p><p>30/ 30 - 7ds ARN VZV Pos VZV Pos/ 34</p><p>P, present; A, absent; Neg, negative; Toxo, toxoplasmosis; IT, immusuppressive therapy or systemic corticosteroid; AC, anterior chamber inflammation; granul/ granulomateous; VC: viral charge, ds: days; M: months; wks: weeks, ARN: acute retinal necrosis; Pos: positive; Neg: negative; NP: not performed. IT: inferotemporal; ST: superotemporal; post pole: posterior pole.</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    3 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us